RT Journal Article
SR Electronic
T1 Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260808
DO 10.1101/2021.07.19.21260808
A1 Christensen, Paul A.
A1 Olsen, Randall J.
A1 Long, S. Wesley
A1 Subedi, Sishir
A1 Davis, James J.
A1 Hodjat, Parsa
A1 Walley, Debbie R.
A1 Kinskey, Jacob C.
A1 Saavedra, Matthew Ojeda
A1 Pruitt, Layne
A1 Reppond, Kristina
A1 Shyer, Madison N.
A1 Cambric, Jessica
A1 Gadd, Ryan
A1 Thakur, Rashi M.
A1 Batajoo, Akanksha
A1 Mangham, Regan
A1 Pena, Sindy
A1 Trinh, Trina
A1 Yerramilli, Prasanti
A1 Nguyen, Marcus
A1 Olson, Robert
A1 Snehal, Richard
A1 Gollihar, Jimmy
A1 Musser, James M.
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.07.19.21260808.abstract
AB Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic. Delta variants of concern are now the focus of intense international attention because they are causing widespread COVID-19 disease globally and are associated with vaccine breakthrough cases. We sequenced the genomes of 12,221 SARS-CoV-2 from samples acquired March 15, 2021 through August 26, 2021 in the Houston Methodist hospital system. This sample represents 88% of all Methodist system COVID-19 patients during the study period. Delta variants increased rapidly from late April onward to cause 99.7% of all COVID-19 cases and spread throughout the Houston metroplex. Compared to other variants, Delta caused a significantly higher rate of vaccine breakthrough cases (23.4% compared to 6.2% for all other variants combined). Importantly, significantly fewer fully vaccinated individuals required hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. Patients infected with Alpha and Delta variants had several significant differences. Our integrated analysis emphasizes that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported by the Houston Methodist Academic Institute Infectious Diseases Fund and many generous Houston philanthropists. James Davis was funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome data used in this study have been deposited to GISAID. https://www.gisaid.org